<DOC>
	<DOCNO>NCT00344773</DOCNO>
	<brief_summary>The purpose study evaluate overall objective tumor response rate ( ORR ) Gefitinib .</brief_summary>
	<brief_title>First-line Treatment Adenocarcinoma Patients With Epidermal Growth Factor Receptor ( EGFR ) Mutation</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Patients require histological biopsy paraffin block 5mg original tumour metastatic site perform EGFR mutational analysis WHO Performance Status 02 No prior chemotherapy , biological immunological therapy/surgery Any evidence clinically active interstitial lung disease Newly diagnose CNS metastasis yet definitively treat surgery /radiation Patients previously diagnose treated CNS metastases spinal cord compression</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Locally advanced ( IIIB ) pulmonary adenocarcinoma EGFR mutation</keyword>
	<keyword>Metastatic ( IV ) pulmonary adenocarcinoma EGFR mutation</keyword>
	<keyword>Recurrent pulmonary adenocarcinoma EGFR mutation</keyword>
</DOC>